Pharmanovia expands its footprint in China with the acquisition of Rocaltrol® from Roche

Pharmanovia has acquired the commercial rights in China for Rocaltrol® (calcitriol) Roche. Pharmanovia obtained the global rights for Rocaltrol® (calcitriol) (excluding Japan and China) In 2020 and the addition of the Chinese rights enhances its osteoporosis range, as well as facilitating a significant expansion of its footprint in China.  Rocaltrol® (calcitriol) is used as an active form of Vitamin D, primarily in the treatment of patients with postmenopausal osteoporosis and renal osteodystrophy.

Pharmanovia has significantly increased its product portfolio since inception in 2013 through its strong relationships with leading pharma companies. The acquisition is a further step in its ability to commercialise and market iconic branded prescription medicines that patients, prescribers, healthcare systems and regulators trust and value.

“This acquisition strengthens our Endocrinology franchise, a strategic focus area for Pharmanovia, and one with several other expansions underway around the globe. Rocaltrol® has been in the market since 1978 and is a highly recognized brand among patients and prescribers. It is an important step in growing our portfolio of high-quality brands and gives us a deeper presence in China”, says James Burt, CEO of Pharmanovia.

This transaction also underlines the company’s strong track record of being a preferred acquirer for large-cap or specialty pharma companies choosing to divest their established brands.